Loading..

BioMarin Pharmaceutical Inc. - Special Call

2022-06-24 11:16:00

To discuss the CHMP decision

BioMarin Pharmaceutical Inc. Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A

2022-06-24 11:16:00

BioMarin Pharmaceutical Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization (CMA) for its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A. A final approval decision, typically consistent with the CHMP recommendation, is expected from the European Commission in Third Quarter 2022. The one-time infusion is planned to be marketed under the brand name ROCTAVIAN™ (valoctocogene roxaparvovec), for the treatment of severe hemophilia A (congenital factor VIII deficiency) in adult patients without a history of factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5). Roctavian is the first gene therapy to be recommended for approval in Europe for hemophilia A. It is estimated that more than 20,000 adults across Europe, Middle East, and Africa are affected by severe hemophilia A. BioMarin anticipates additional patient access through named patient sales based on an EMA approval in countries in the Middle East and Arica and expects additional market registrations to be facilitated by an anticipated EMA license. People with hemophilia A have a mutation or irregularity in the gene responsible for producing Factor VIII (FVIII), a protein necessary for blood clotting. The standard of care for patients with severe hemophilia A is chronic lifelong injectable therapy to maintain enough clotting factor in the bloodstream to prevent bleeds. Investigational valoctocogene roxaparvovec gene therapy works by delivering a functional gene that is designed to enable the body to produce FVIII on its own with the goal of reducing the need for ongoing prophylaxis. The CHMP based its positive opinion on the totality of data from the valoctocogene roxaparvovec clinical development program, the most extensively studied gene therapy for hemophilia A, including two-year outcomes from the global GENEr8-1 Phase 3 study, supported by five and four years of follow-up from the 6e13 vg/kg and 4e13 vg/kg dose cohorts respectively, in the ongoing Phase 1/2 dose escalation study. BioMarin has committed to continue working with the broader community to monitor the long-term effects of treatment. The CHMP is a scientific committee composed of representatives from the 27-member states of the EU, and Iceland, Norway, and Liechtenstein. The committee reviews medical product applications on its scientific and clinical merit and provides advice to the European Commission (EC), which has the authority to approve medicines for the EU. A conditional marketing authorization (CMA) recognizes that benefit to public health of the immediate availability on the market outweighs the uncertainties inherent to the fact that the science is still new, as is the case with any gene therapy, and the fact that additional data are still required. Once a CMA has been granted by EMA, BioMarin will provide further data from ongoing studies within defined timelines to confirm that the benefits continue to outweigh the risks, building on what already constitutes the largest clinical data package for gene therapy in hemophilia A. Conversion to a standard marketing authorization will be contingent on the provision of additional data from currently ongoing Roctavian clinical studies, including longer-term follow up of patients enrolled in the pivotal trial GENEr8-1, as well as a study of corticosteroids for which enrollment is now complete. The final summary of product characteristics willbe available when the product is approved by the European Commission. Robust Clinical ProgramBioMarin has multiple clinical studies underway in its comprehensive gene therapy program for the treatment of hemophilia A. In addition to the global Phase 3 study GENEr8-1 and the ongoing Phase 1/2 dose escalation study, the Company is also conducting a Phase 3B, single arm, open-label study to evaluate the efficacy and safety of valoctocogene roxaparvovec at a dose of 6e13 vg/kg with prophylactic corticosteroids in people with hemophilia A (Study 270-303). In addition, the Company is running a Phase 1/2 Study with the 6e13 vg/kg dose of valoctocogene roxaparvovec in people withhemophilia A with pre-existing AAV5 antibodies (Study 270-203), as well as another Phase 1/2 Study with the 6e13 vg/kg dose of valoctocogene roxaparvovec in people with hemophilia A with active or prior FVIII inhibitors (Study 270-205). Safety Summary Overall, single 6e13 vg/kg dose of valoctocogene roxaparvovec has been well tolerated with no delayed-onset treatment.

BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed

2022-06-21 20:02:00

BioMarin Pharmaceutical Inc. announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan granted approval of the registration of VOXZOGO (vosoritide) for injection, indicated for the treatment of achondroplasia in children of all ages, whose growth plates are not closed. Voxzogo, a modified C-type natriuretic peptide (CNP), directly targets the underlying pathophysiology of achondroplasia by down regulating fibroblast growth factor receptor 3 (FGFR3) signaling and consequently promoting endochondral bone formation. The MHLW in Japan based its decision on the outcomes of a global Phase 3 randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Voxzogo and the long-term extension of this Phase 3 study as well as data from patients participating in a Phase 2 randomized, double-Blind, placebo-controlled clinical trial evaluating the safety and efficacy of Voxzogo in infants and young children with achondroplasia, age 0 to < 60 months. In 2021, Voxzogo received approvals in the United States, Europe and Brazil. Achondroplasia, the most common form of skeletal dysplasia leading to disproportionate short stature, is characterized by slowing of endochondral bone growth, which results in disproportionate short stature and disordered architecture in the long bones, spine, face and base of the skull. This condition is caused by a gain of function mutation in the fibroblast growth factor receptor 3 gene (FGFR3), a negative regulator of bone growth. More than 80% of children with achondroplasia have parents of average stature and have the condition as the result of a spontaneous change in the gene. Around 25% of individuals living with achondroplasia have open growth plates. The worldwide incidence rate of achondroplasia is about one in 25,000 live births. Safety and efficacy of Voxzogo in patients with achondroplasia were assessed in one 52–week, multi–center, randomized, double–blind, placebo–controlled, Phase 3 study. Transient decreases in blood pressure have been observed with Voxzogo. In the clinical study, 8 (13%) of 60 patients treated with Voxzogo had a total of 11 events of transient decreases in blood pressure compared to 3 (5%) of 61 patients on placebo, over a 52-week treatment period. Patients with significant cardiac or vascular disease or on anti-hypertensive medicine were excluded from the trial. To reduce the risk of a decrease in blood pressure and associated symptoms (dizziness, fatigue and/or nausea), patients should be well hydrated and have adequate food intake prior to administration. The most common adverse reactions, occurring in greater than or equal to 5% of patients treated with Voxzogo and at a percentage greater than placebo in the Phase 3 study are injection site reactions (including redness, itching, swelling, bruising, rash, hives, pain), vomiting, joint pain, decreased blood pressure, gastroenteritis, diarrhea, dizziness, ear pain, influenza, fatigue, seasonal allergy, and dry skin. In the United States, VOXZOGO is a prescription medicine used to increase linear growth in children with achondroplasia who are 5 years of age and older with open growth plates (epiphyses). VOXZOGO is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

BioMarin Pharmaceutical Inc. Announces Favorable Results from Global Phase 2 Study of Voxzogo™ (Vosoritide) for Injection in Infants and Young Children with Achondroplasia At the Endocrine Society Annual Meeting

2022-06-13 16:31:00

BioMarin Pharmaceutical Inc. presented data at The Endocrine Society Annual Meeting, ENDO 2022, demonstrating the Company's ongoing commitment to understanding the lifetime impact of achondroplasia, the most common form of disproportionate short stature. The Company provided data from a Phase 2 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of VOXZOGO™ (vosoritide) for Injection in infants and children aged 0 to less than five years old. In the overall population of all randomized and sentinel subjects, the study showed an improvement in height Z-score (a measure of height adjusted for age and sex in reference to the average stature population and reported as a Standard Deviation, SD) as compared to placebo at 52 weeks. Voxzogo (n=43), compared to placebo (n=32), increased height Z-score by 0.30 SD (95% CI 0.07, 0.54) and annualized growth velocity (AGV) by 0.92cm/year (95% CI 0.24, 1.59). This improvement in height Z-score was consistent with improvements previously observed after one year of treatment in children over five years of age. In the randomized population (excluding sentinel subjects) and in the individual age subgroups, a trend toward increased height Z-score was observed. Voxzogo did not significantly impact upper-to-lower body segment ratio, which changed by -0.06 (95% CI -0.15, 0.03) over this 52-week period. BioMarin intends to meet with regulatory health authorities in the second half of 2022 to discuss next steps to expand access to Voxzogo for the treatment of achondroplasia in younger children. The safety profile was generally consistent with that seen in older subjects in the Phase 3 Voxzogo 301 study (the current label population). Serious Adverse Events (SAEs) were higher in the placebo group (18%) compared to Voxzogo-treated children (7%). All SAEs, including a fatal respiratory arrest (reported as a sudden infant death syndrome in a treated infant with pre-existing respiratory morbidity), were deemed by the investigators to be unrelated to treatment. The most common adverse events were mild and self-limiting injection site reactions. See the U.S. Important Safety Information below and full Prescribing Information and Patient Prescribing Information for additional safety information. The 52-week phase 2 study enrolled 75 infants and young children with achondroplasia, aged zero to less than five years old (60 months). The study consists of three cohorts by age (24 months to less than 5 years, 6 months to less than 24 months, less than 6 months) and is followed by a subsequent open-label extension trial where all children receive active treatment. Children in this study will have completed a minimum three- or six-month baseline study to determine their respective baseline growth prior to entering the Phase 2 study. The objectives of the study are to evaluate safety, tolerability, and the effect of Voxzogo on growth. The study also evaluated proportionality, functionality, quality of life, sleep apnea, and foramen magnum dimension, as well as the advent of major illnesses and surgeries which frequently occur in children with achondroplasia.

BioMarin Pharmaceutical Inc. Announces Durable Hemostatic Efficacy Maintained over 6 Years in Ongoing Phase 1 2 Study of Valoctocogene Roxaparvovec

2022-05-31 12:31:00

BioMarin Pharmaceucal Inc. announced updated results from its ongoing open-label Phase 1/2 study, which represents the longest duration of clinical observation for valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A. The Company plans to share the data during an oral presentation at the upcoming International Society on Thrombosis and Haemostasis 2022 Congress. Six-year and five-year post-treatment follow-up of the 6e13 vg/kg and 4e13 vg/kg cohorts, respectively, demonstrated sustained hemostatic efficacy of valoctocogene roxaparvovec. 6-Year Results in Phase 1/2 6e13 vg/kg Dose Cohort All participants in the 6e13 vg/kg cohort remain off prophylactic Factor VIII treatment at the time of the data cut. The mean cumulative annualized bleed rate remains less than one and substantially below baseline levels; the mean ABR in year six was 0.7 with a mean cumulative ABR reduction of 95% and Factor VIII use reduction of 96% through six years, compared to baseline. 5-Year Results in Phase 1/2 4e13 vg/kg Dose Cohort All participants in the 4e13 vg/kg cohort were off prophylactic Factor VIII at the time of the data cut. Six months prior to the data cut, one participant temporarily resumed prophylactic Factor VIII treatment for one month, after which he was bleed free through the last follow up. The mean ABR in year five for the 4e13 vg/kg cohort was 0.7 with a mean cumulative ABR reduction of 91% and Factor VIII use reduction of 93% through five years, compared to baseline. The trajectory of Factor VIII activity levels in both the 6e13 vg/kg and 4e13 vg/kg cohorts were commensurate with the most recent years' observations. Regulatory StatusBioMarin plans to include the previously reported results from the two-year follow-up safety and efficacy data from the Phase 3 GENEr8-1 study in a Biologics Licensing Application resubmission for valoctocogene roxaparvovec to the Food and Drug Administration. Based on recent feedback received from the FDA related to BioMarin's plans for the upcoming BLA, the Agency has requested additional information and analyses of data to be included in the BLA prior to submission. The FDA has not requested additional pre-clinical or clinical studies. While at present, no requests have been made concerning evaluation of efficacy and safety three years after dosing from the GENEr8-1 study, BioMarin is aware that such data will become available during the anticipated BLA review. Based on these new information requests, the BLA resubmission is now expected by the end of September. The FDA granted Regenerative Medicine Advanced Therapy designation to valoctocogene roxaparvovec in March 2021. RMAT is an expedited program intended to facilitate development and review of regenerative medicine therapies, such as valoctocogene roxaparvovec, that are intended to address an unmet medical need in patients with serious conditions. The RMAT designation is complementary to Breakthrough Therapy Designation, which the Company received in 2017. In addition to the RMAT Designation and Breakthrough Therapy Designation, BioMarin's valoctocogene roxaparvovec also has received orphan drug designation from the FDA and EMA for the treatment of severe hemophilia A. The Orphan Drug Designation program is intended to advance the evaluation and development of products that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions. The European Medicines Agency continues the review of BioMarin's Marketing Authorization Application for valoctocogene roxaparvovec, and anticipate a Committee for Medicinal Products for Human Use opinion mid-year 2022. BioMarin has provided the EMA with two-year follow-up safety and efficacy data from the GENEr8-1 study. Safety Summary Overall, the safety profile of valoctocogene roxaparvovec in the Phase 1/2 study remains consistent with previously reported data with no delayed-onset treatment related adverse events. All participants continue to remain off corticosteroids since the first year. No participants developed inhibitors to Factor VIII, and no participants withdrew from the study. No participants have developed thrombotic events. The most common adverse events associated with valoctocogene roxaparvovec occurred early after a single infusion and included short-lived infusion-associated reactions and transient, asymptomatic, and mild to moderate rise in the levels of certain proteins and enzymes measured in liver function tests with no long-lasting clinical sequelae. A Serious Adverse Event of a parotid acinic cell carcinoma was identified in one study participant, who was treated more than five years ago, and was reported as unrelated to valoctocogene roxaparvovec by the investigator. The study participant was successfully treated. The relevant health authorities were notified, and all studies remain ongoing without modification. The independent Data Monitoring Committee (DMC) further reviewed the case. A genomic analysis was conducted as prespecified in the clinical trial protocol and the findings from the completed analysis showed a comparable pattern of integration between healthy and tumor containing tissues, with no evidence emerging that vector integration contributed to the salivary gland mass.

BioMarin Pharmaceutical Inc. Presents at DIA Global Annual Meeting 2022, Jun-19-2022

2022-05-28 18:13:00

BioMarin Pharmaceutical Inc. Presents at DIA Global Annual Meeting 2022, Jun-19-2022 . Venue: Chicago, Illinois, United States. Speakers: Ebony Dashiell-Aje, Head and Senior Director, Patient Engagement and Outcomes Research.

BioMarin Pharmaceutical Inc. Announces Executive Appointments

2022-05-05 20:04:00

BioMarin Pharmaceutical Inc. announced that the company hired Humaira Serajuddin as Senior Vice President, Chief Marketing Officer and Erin Burkhart as Group Vice President, Chief Accounting Officer, filling two key strategic roles supporting BioMarin's growth goals. Serajuddin brings a significant depth and breadth of commercial experience, having held both operational and strategic roles in positions across multiple functions, as well as international experience across multiple specialty areas. In this newly created role, Serajuddin is charged with evolving BioMarin's global product strategy and lifecycle management to prepare BioMarin for expected transformational growth as the Company moves into more competitive and large markets. Serajuddin will be working closely with cross-functional teams to set strategy and execute on corporate goals. Most recently, she spent over a decade at GlaxoSmithKline plc (GSK) in leadership positions of increasing responsibility at both global and country levels. Burkhart is a highly experienced accounting and finance executive with deep technical accounting skills, global corporate finance experience, biopharma business acumen and leadership capabilities. She brings robust accounting experience across a number of specialized areas, large-scale business operating model experience, and a successful track record of leading transformational business initiatives. In this role, Burkhart will assume principal accounting officer responsibilities, including setting BioMarin's global accounting vision and strategy, team leadership, global controllership and accounting operations and systems, and maintaining accounting policies and financial internal controls. With more than 20 years of accounting and finance experience, Burkhart most recently held accounting roles of increasing responsibility at Eli Lilly & Co., which include leading accounting operations second to the Chief Accounting Officer.

BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress

2022-05-05 12:31:00

BioMarin Pharmaceutical Inc. announced five platform presentations and one poster presentation on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the World Federation of Hemophilia (WFH) 2022 World Congress from May 8-11 in Montreal, Canada. Presentation of data at WFH follows positive two-year results from the ongoing, global phase 3 GENEr8-1 study of valoctocogene roxaparvovec presented at a medical meeting earlier in the year, as well as publication of one-year results from the pivotal clinical trial in the New England Journal of Medicine in March 2022.

BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2022

2022-04-27 20:02:00

BioMarin Pharmaceutical Inc. provided earnings guidance for the full year 2022. For the period, the company expects total revenue to be in the range of $2,050 million and $2,150 million and GAAP net income to be in the range of $95 million and $135 million.

BioMarin Pharmaceutical Inc. Presents at TIDES (Oligonucleotide & Peptide Therapeutics), May-05-2022

2022-04-23 17:57:00

BioMarin Pharmaceutical Inc. Presents at TIDES (Oligonucleotide & Peptide Therapeutics), May-05-2022 . Venue: Boston, Massachusetts, United States. Speakers: Charles O'Neill, Vice President, Early Drug Development Solutions.

I.I.R Ltd., TIDES (Oligonucleotide & Peptide Therapeutics), May 05, 2022 through May 12, 2022

2022-04-23 07:45:00

I.I.R Ltd., TIDES (Oligonucleotide & Peptide Therapeutics), May 05, 2022 through May 12, 2022. Venue: Boston, Massachusetts, United States.

BioMarin Pharmaceutical Inc. Presents at Cell & Gene Meeting on the Mediterranean, Apr-19-2022

2022-04-17 03:23:00

BioMarin Pharmaceutical Inc. Presents at Cell & Gene Meeting on the Mediterranean, Apr-19-2022 . Venue: Barcelona, Spain.

BioMarin Pharmaceutical Inc., Q1 2022 Earnings Call, Apr 27, 2022

2022-04-13 13:00:00

BioMarin Pharmaceutical Inc., Q1 2022 Earnings Call, Apr 27, 2022

BioMarin Pharmaceutical Inc., Annual General Meeting, May 24, 2022

2022-04-12 20:31:00

BioMarin Pharmaceutical Inc., Annual General Meeting, May 24, 2022, at 09:00 Pacific Standard Time. Agenda: To elect the 11 nominees for director named in the proxy statement accompanying this Notice of Annual Meeting of Stockholders to serve until the next Annual Meeting and until their successors are duly elected and qualified; to ratify the selection of KPMG LLP (KPMG) as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2022; to approve, on an advisory basis, the compensation of the Company’s Named Executive Officers (NEOs) as disclosed in the Proxy Statement; and to conduct any other business properly brought before the Annual Meeting.

BioMarin Pharmaceutical Inc. - Shareholder/Analyst Call

2022-04-12 20:31:00

Annual Meeting of Stockholders

Hanson Wade Limited, 2nd Annual Gene Therapy Patient Engagement Summit, Jun 07, 2022 through Jun 09, 2022

2022-04-06 17:15:00

Hanson Wade Limited, 2nd Annual Gene Therapy Patient Engagement Summit, Jun 07, 2022 through Jun 09, 2022. Venue: Boston, Massachusetts, United States.

BioMarin Pharmaceutical Inc. Presents at 2nd Annual Gene Therapy Patient Engagement Summit, Jun-07-2022

2022-04-06 17:15:00

BioMarin Pharmaceutical Inc. Presents at 2nd Annual Gene Therapy Patient Engagement Summit, Jun-07-2022 . Venue: Boston, Massachusetts, United States. Speakers: Kristen Bostrom, Associate Director, Global Patient Advocacy & Engagement.

BioMarin Pharmaceutical Inc. Presents at Bank of America 2022 Healthcare Conference, May-12-2022 08:40 AM

2022-03-22 05:03:00

BioMarin Pharmaceutical Inc. Presents at Bank of America 2022 Healthcare Conference, May-12-2022 08:40 AM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Brian R. Mueller, Executive VP of Finance, CFO & Principal Accounting Officer, Jean-Jacques Bienaime, Chairman & CEO.

Alliance for Regenerative Medicine, Cell & Gene Meeting on the Mediterranean, Apr 19, 2022 through Apr 21, 2022

2022-02-26 07:53:00

Alliance for Regenerative Medicine, Cell & Gene Meeting on the Mediterranean, Apr 19, 2022 through Apr 21, 2022. Venue: Barcelona, Spain.

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.

BioMarin Announces Oral Presentation of 2-Year Analysis of Large Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A

2022-02-04 16:15:00

BioMarin Pharmaceutical Inc. announced that the Company presented positive results from a two-year analysis of the Phase 3 GENEr8-1 study and an overall safety update of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the 15th Annual Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD). This is the large global Phase 3 study to date for any gene therapy in hemophilia with 134 participants. In the GENEr8-1 Phase 3 study, Annualized Bleeding Rate (ABR) was significantly reduced by 4.1 treated bleeds per year (p-value <0.0001), or by 85% from a baseline mean of 4.8 (median 2.8), in the pre-specified primary analysis in participants from a prior non-interventional study (rollover population; N=112; median follow-up of 110 weeks). The percentage of participants with zero treated bleeds increased from 32% on prophylaxis at baseline to 82% during year 1 and 84% during year 2. The mean ABR was 0.8 (median 0.0) through the entire efficacy evaluation period, 0.9 (median 0.0) during year one, and 0.7 (median 0.0) during year two. Across all participants in the rollover population (N=112), mean annualized Factor VIII infusion rate was reduced by 133 infusions per year (p-value <0.0001) or 98% from baseline. As of the two-year data cut, 95% of participants remain off Factor VIII prophylactic therapy.

BioMarin Pharmaceutical Inc. Presents at SCOPE Summit 2022, Feb-10-2022 10:55 AM

2022-02-04 08:35:00

BioMarin Pharmaceutical Inc. Presents at SCOPE Summit 2022, Feb-10-2022 10:55 AM. Venue: Orlanda, Florida, United States. Speakers: Ebony N Dashiell-Aje, Senior Director, Patient Engagement and Outcomes Research.

BioMarin Pharmaceutical Inc. Presents at 15th EAHAD Congress, Feb-02-2022

2022-02-02 21:04:00

BioMarin Pharmaceutical Inc. Presents at 15th EAHAD Congress, Feb-02-2022 .

European Association For Haemophilia And Allied Disorders Limited, 15th EAHAD Congress, Feb 02, 2022 through Feb 04, 2022

2022-01-31 12:32:00

European Association For Haemophilia And Allied Disorders Limited, 15th EAHAD Congress, Feb 02, 2022 through Feb 04, 2022.

BioMarin Pharmaceutical Inc. and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular Diseases

2021-12-16 21:05:00

BioMarin Pharmaceutical Inc. and Skyline Therapeutics announced a multi-year global strategic collaboration for the discovery, development and commercialization of Adeno-Associated Virus (AAV) gene therapies to treat genetic cardiovascular diseases. The partnership will leverage Skyline Therapeutics' integrated AAV gene therapy platform based on its proprietary vector engineering and design technology and manufacturing capability to develop innovative gene therapies with a focus on genetic dilated cardiomyopathies (DCM), a group of progressively advancing, devastating diseases with no targeted treatment options. Under the agreement, BioMarin and Skyline Therapeutics will collaborate on discovery and research through to an Investigational New Drug Application (IND). BioMarin brings experience in gene therapy development, cardiovascular biology and insights into genetic basis of diseases, and Skyline contributes its expertise in developing gene therapy products including vector engineering and design technology and manufacturing capabilities to this collaboration. Each company will advance the programs through clinical development in their pre-defined territories. In support of its R&D efforts for the collaborative projects, Skyline Therapeutics will receive an undisclosed payment associated with signing, comprising an upfront payment and an equity investment from BioMarin, and is eligible to receive pre-specified payments for R&D, regulatory and commercial milestones. BioMarin will have the rights to commercialize therapeutic products resulting from the collaboration in its territories, including the United States, Europe, and Latin America, and Skyline Therapeutics will be responsible for commercialization in the Asia-Pacific region. In addition, Skyline Therapeutics will be eligible to receive royalty payments on future sales from BioMarin in its territories.

BioMarin Pharmaceutical Inc. Appoints Mark Alles to Board of Directors and to the Audit Committee of the Board, Effective January 1, 2022

2021-12-15 21:05:00

BioMarin Pharmaceutical Inc. announced the appointment of former CEO of Celgene Corporation, Mark Alles, to its Board of Directors and to the Audit Committee of the Board effective January 1, 2022.

Drug Information Association, Inc., DIA Global Annual Meeting 2022, Jun 19, 2022 through Jun 23, 2022

2021-12-10 06:32:00

Drug Information Association, Inc., DIA Global Annual Meeting 2022, Jun 19, 2022 through Jun 23, 2022. Venue: Chicago, Illinois, United States.

ROSEN, A LEADING LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Important December 22 Deadline in Securities Class Action

2021-12-07 17:18:00

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. between January 13, 2020 and September 3, 2021, inclusive (the “Class Period”), of the important December 22, 2021 lead plaintiff deadline. encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the large ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

BioMarin Pharmaceutical Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 01:25 PM

2021-11-29 13:30:00

BioMarin Pharmaceutical Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 01:25 PM.

BioMarin Pharmaceutical Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Dec-02-2021 01:30 PM

2021-11-22 15:06:00

BioMarin Pharmaceutical Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Dec-02-2021 01:30 PM. Venue: New York, New York, United States. Speakers: Brian R. Mueller, Executive VP of Finance & CFO, Jean-Jacques Bienaime, Chairman & CEO.

BioMarin Pharmaceutical Inc. - Analyst/Investor Day

2021-11-20 04:04:00

R&D Day 2021

BioMarin Pharmaceutical Inc. - Special Call

2021-11-19 15:42:00

To discuss U.S. FDA Approval for VOXZOGO

Biomarin Pharmaceutical Inc. Receives FDA Approval for Voxzogo™ (Vosoritide) for Injection

2021-11-19 15:42:00

BioMarin Pharmaceutical Inc. announced that the U.S. Food and Drug Administration has granted accelerated approval to VOXZOGO™ (vosoritide) for Injection, indicated to increase linear growth in pediatric patients with achondroplasia five years of age and older with open epiphyses (growth plates). This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory studies. To fulfill this post-marketing requirement, BioMarin intends to use the ongoing open-label extension studies compared to available natural history. Voxzogo is the first FDA approved treatment for children with achondroplasia. In patients with achondroplasia, endochondral bone growth, an essential process by which bone tissue is created, is negatively regulated due to a gain of function mutation in fibroblast growth factor receptor 3 gene (FGFR3). Voxzogo, a C-type natriuretic peptide (CNP) analog, represents a new class of therapy, which acts as a positive regulator of the signaling pathway downstream of FGFR3 to promote endochondral bone growth. With this approval, the FDA also issued a Rare Pediatric Disease Priority Review Voucher (PRV), which confers priority review to a subsequent drug application that would not otherwise qualify for priority review. The rare pediatric disease PRV program is designed to encourage development of new drugs and biologics for the prevention or treatment of rare pediatric diseases.Voxzogo is expected to be available in the United States by mid- to late-December, and BioMarin will begin the promotion of Voxzogo immediately. The approval was based on the outcomes of a global randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of Voxzogo and the open-label extension of this Phase 3 study. The study enrolled 121 children aged 5 to 14.9 with achondroplasia. Baseline mean AGV in the placebo and Voxzogo groups was 4.06 cm/year and 4.26 cm/year, respectively. At week 52, the change from baseline in AGV was -0.17 cm/year for the placebo treated patients and 1.40 cm/year for the Voxzogo treated patients, resulting in a statistically significant improvement in AGV of 1.57 cm/year in favor of Voxzogo. After the 52 week double blind, placebo–controlled, phase 3 study, 58 subjects initially randomized to Voxzogo enrolled into an open–label extension. Among the subjects who had two years of follow–up since randomization, the improvement in AGV was maintained. In August 2021, the European Commission (EC) approved Voxzogo. Marketing authorization reviews are in process in Japan, Brazil, and Australia with potential approvals in these countries in 2022.

BioMarin Pharmaceutical Inc. Announces Management Changes, Effective January 28, 2022

2021-11-03 20:06:00

On October 29, 2021, Andrea Acosta, the Group Vice President, Chief Accounting Officer, and principal accounting officer of BioMarin Pharmaceutical Inc. notified BioMarin of her decision to resign, effective as of January 28, 2022, in order to pursue another career opportunity. Brian Mueller, BioMarin's Executive Vice President, Finance and Chief Financial Officer, will serve as the company's principal accounting officer from the effective date until Ms. Acosta's successor is appointed. Mr. Mueller will continue to serve as BioMarin's Executive Vice President, Finance and Chief Financial Officer.

BioMarin Pharmaceutical Inc. Presents at Pharma & Patient USA, Nov-02-2021 through Nov-04-2021

2021-10-30 00:55:00

BioMarin Pharmaceutical Inc. Presents at Pharma & Patient USA, Nov-02-2021 through Nov-04-2021. Presentation Date & Speakers: Nov-02-2021, Ebony Dashiell-Aje, Senior Director, Patient Engagement and Outcomes Research.

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Bragar Eagel & Squire, P.C. Announces Class Action Lawsuit Filed Against BioMarin Pharmaceuticals

2021-10-28 01:00:00

Bragar Eagel & Squire, P.C. announced that a class action lawsuit has been filed against BioMarin Pharmaceuticals in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired BioMarin securities between January 1, 2020 and September 3, 2021, both dates inclusive (the “Class Period”). Investors have until December 21, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit. According to the filed complaint: BMN 307 was less safe than BioMarin had led investors to believe; BMN 307’s safety profile made it likely that the FDA would place a clinical hold on the Phearless Phase 1/2 study; accordingly, the Company had overstated BMN 307’s clinical and commercial prospects; and as a result, the Company’s public statements were materially false and misleading at all relevant times.

BioMarin Pharmaceutical Inc. Revises Earnings Guidance for the Full Year 2021

2021-10-27 20:14:00

BioMarin Pharmaceutical Inc. revised earnings guidance for the full year 2021. For the year, the company expected Total Revenues of $1,820 million to $1,880 million against $1,790 million to $1,880 million as announced earlier. GAAP Net Loss of $85 million to $45 million against $110 million to $60 million as announced earlier.

BioMarin Pharmaceutical Inc. Presents at Jefferies Gene Therapy/Editing Summit, Oct-28-2021 02:30 PM

2021-10-25 12:34:00

BioMarin Pharmaceutical Inc. Presents at Jefferies Gene Therapy/Editing Summit, Oct-28-2021 02:30 PM.

BioMarin Pharmaceutical Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-17-2021 11:20 AM

2021-10-25 12:34:00

BioMarin Pharmaceutical Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-17-2021 11:20 AM. Venue: New York, New York, United States.

BioMarin Pharmaceutical Inc. Presents at Barclays Gene Editing & Gene Therapy Summit 2021, Nov-15-2021 04:00 PM

2021-10-25 12:34:00

BioMarin Pharmaceutical Inc. Presents at Barclays Gene Editing & Gene Therapy Summit 2021, Nov-15-2021 04:00 PM.

Pomerantz LLP Files Class Action Against Biomarin Pharmaceutical Inc. and Certain Officers

2021-10-23 04:00:00

Pomerantz LLP announced that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-08254, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired BioMarin securities between January 13, 2020 and September 3, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) BMN 307 was less safe than BioMarin had led investors to believe; (ii) BMN 307's safety profile made it likely that the FDA would place a clinical holdon the Phearless Phase 1/2 study; (iii) accordingly, the Company had overstated BMN 307's clinical and commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Barclays PLC, Barclays Gene Editing & Gene Therapy Summit 2021, Nov 15, 2021 through Nov 16, 2021

2021-10-20 20:00:00

Barclays PLC, Barclays Gene Editing & Gene Therapy Summit 2021, Nov 15, 2021 through Nov 16, 2021.

BioMarin Pharmaceutical Inc., Q3 2021 Earnings Call, Oct 27, 2021

2021-10-12 12:30:00

BioMarin Pharmaceutical Inc., Q3 2021 Earnings Call, Oct 27, 2021

BioMarin Pharmaceutical Inc. Hires Harold S. Bernstein as Chief Medical Officer and Head of Clinical Development

2021-10-04 12:31:00

BioMarin Pharmaceutical Inc. announced that the company hired Harold S. Bernstein as Chief Medical Officer and Head of Clinical Development. In this role, Bernstein will be responsible for fortifying clinical development from early to late stages, working seamlessly with research discovery and overseeing the late stage and life cycle products. Most recently, Dr. Bernstein was Head of Translational Medicine, and Vice President of Global Medicines Development at Vertex.

BioMarin Pharmaceutical Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-10-2021 01:50 PM

2021-10-01 10:34:00

BioMarin Pharmaceutical Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-10-2021 01:50 PM. Venue: Rancho Palos Verdes, California, United States. Speakers: Brian R. Mueller, Executive VP & CFO, Jean-Jacques Bienaime, Chairman & CEO.

Jefferies LLC, Jefferies Gene Therapy/Editing Summit, Oct 27, 2021 through Oct 28, 2021

2021-09-30 11:05:00

Jefferies LLC, Jefferies Gene Therapy/Editing Summit, Oct 27, 2021 through Oct 28, 2021.

BioMarin Pharmaceutical Inc. Presents at Cell & Gene Meeting on the Mesa, Oct-12-2021

2021-09-27 23:05:00

BioMarin Pharmaceutical Inc. Presents at Cell & Gene Meeting on the Mesa, Oct-12-2021 . Venue: Carlsbad, California, United States.

Biomarin Pharmaceutical Inc. Announces U.S. FDA Placed Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-Clinical Study Findings

2021-09-06 06:00:00

BioMarin Pharmaceutical Inc. announced that the U.S Food and Drug Administration (FDA) placed a clinical hold on the BMN 307 Phearless Phase 1/2 study. The Phearless study is evaluating BMN 307, an investigational AAV5-phenylalanine hydroxylase (PAH) gene therapy, in adults with phenylketonuria (PKU). The FDA's clinical hold was based on interim safety findings from a pre-clinical, non-GLP pharmacology study. The Company carried out this pre-clinical study to understand the durability of BMN 307 activity in mice bearing two germline mutations, which may predispose the mice to the development of malignancy. One mutation eliminated the PAH gene that's missing in PKU and the second rendered the animals immunodeficient. Of 63 animals treated, six of seven animals administered BMN 307 at the dose group (2e14 Vg/kg) had tumors on liver necropsy 52 weeks after dosing with evidence for integration of portions of AAV vector into the genome. No lesions were observed in any mice at 24 weeks. Five of these animals had adenomas and one had a hepatocellular carcinoma (HCC). The translatability of these findings to humans is uncertain and under further investigation. To date, the Company has only dosed humans in the Phearless Phase 1/2 clinical study with lower doses of either 2e13 vg/kg or 6e13 vg/kg. Due in part to the risk previously identified by historical rodent studies, the liver health of Phearless study participants is regularly monitored. The Company will work with the Data Review Board and Principal Investigators to further evaluate the study participants who have been dosed and will continue to monitor them over the long-term. The clinical significance of these pre-clinical rodent findings has not been established and cancers due to AAV integration have not been observed in larger animals or humans. BioMarin is pausing further enrollment into this global Phase 1/2 study until the investigation of these findings is completed. The company is working with the FDA and other health authorities and will communicate next steps for the program when available.

Cambridge Innovation Institute, LLC, SCOPE Summit 2022, Feb 07, 2022 through Feb 10, 2022

2021-09-04 12:00:00

Cambridge Innovation Institute, LLC, SCOPE Summit 2022, Feb 07, 2022 through Feb 10, 2022. Venue: Orlanda, Florida, United States.

European Commission Approves BioMarin’s VOXZOGO (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close

2021-08-27 13:51:00

BioMarin Pharmaceutical Inc. announced that the European Commission (EC) has granted marketing authorization for VOXZOGO (vosoritide), a once daily injection to treat achondroplasia in children from the age of 2 until growth plates are closed, which occurs after puberty when children reach final adult height. Vosoritide is the first medicine to be approved to treat children with achondroplasia in Europe. Vosoritide, a modified C-type natriuretic peptide (CNP), directly targets the underlying pathophysiology of achondroplasia by down regulating fibroblast growth factor receptor 3 (FGFR3) signaling and consequently promoting endochondral bone formation. It is estimated that over 11,000 children across Europe, Middle East, and Africa are affected by achondroplasia and could be eligible for treatment with vosoritide. Approximately a third of this population are in countries authorized under the EMA license. Also, the French National Agency for Medicines and Health Products Safety (ANSM) granted an Autorisation Temporaire d'Utilisation de cohorte (ATU cohort), or Temporary Authorization for Use to allow access of vosoritide to begin immediately under an authorized process. An ATU allows access to drugs not yet approved in France, when provided for rare diseases with no alternative options, and when the benefit/risk is presumed positive. The EC based its decision on the totality of data from the vosoritide clinical development program including the outcomes from the randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of vosoritide. The Phase 3 Study was further supported by the ongoing long-term safety and efficacy from the Phase 2 dose-finding study, which showed that growth rates have been sustained above participants’ baseline rates and above the expected annualized growth velocity for untreated children with achondroplasia throughout the five-year observation period for which data are currently available. No acceleration of bone age was observed, suggesting that vosoritide is not reducing the total duration of growth. The data package included results from an ongoing Phase 2 randomized double-blind study in infants and young children, including extensive pharmacokinetic and biomarker data, as well as preliminary growth data from participants in the 2 to 5-year age cohort. Data in sentinel study participants showed a positive effect on growth following two years of vosoritide treatment in subjects aged 2 to 5 years. In addition, the data package included data from the Phase 3 extension study and extensive natural history data. The U.S. New Drug Application (NDA) for vosoritide is under review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of November 20, 2021. The Company successfully closed out the in-person FDA pre-approval inspection of its manufacturing facilities for vosoritide earlier this year. Vosoritide was generally well tolerated at all doses, and approximately 38,000 injections have been administered to children around the world. The majority of adverse events (AEs) were mild and no serious adverse events (SAEs) were reported as study drug related. Across all doses, injection site reactions and hypotension were the most common drug-related AEs. All injection site reaction events were transient. AEs of hypotension were mild and transient with the majority being asymptomatic and reported in the context of routine blood pressure measurements with minimal clinical impact. No new safety findings were observed. There were no AEs related to disproportionate bone growth or bone pathology. There has been no evidence of accelerated bone age (as assessed by radiologists blinded to the age of the subjects) or negative changes in bone mineral density.

BioMarin Pharmaceutical Inc. Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 12:15 PM

2021-08-26 17:20:00

BioMarin Pharmaceutical Inc. Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 12:15 PM. Speakers: Jean-Jacques Bienaime, Chairman & CEO.

BioMarin Pharmaceutical Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-10-2021 01:15 PM

2021-08-25 12:30:00

BioMarin Pharmaceutical Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-10-2021 01:15 PM. Venue: New Windsor, United States.

BioMarin Pharmaceutical Inc. Presents at J.P. Morgan 12th Annual U.S. All Stars Conference, Sep-22-2021 12:00 PM

2021-08-25 12:30:00

BioMarin Pharmaceutical Inc. Presents at J.P. Morgan 12th Annual U.S. All Stars Conference, Sep-22-2021 12:00 PM.

BioMarin Pharmaceutical Inc. Presents at Bank of America Global Healthcare Conference, Sep-17-2021 12:35 PM

2021-08-25 12:30:00

BioMarin Pharmaceutical Inc. Presents at Bank of America Global Healthcare Conference, Sep-17-2021 12:35 PM. Speakers: JJ Bienaime, Chairman & Chief Executive.

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021

2021-08-10 13:03:00

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.

Reuters Events, Pharma & Patient USA, Nov 02, 2021 through Nov 04, 2021

2021-08-05 03:58:00

Reuters Events, Pharma & Patient USA, Nov 02, 2021 through Nov 04, 2021.

Biomarin Pharmaceutical Inc. Raises Earnings Guidance for the Full Year of 2021

2021-07-28 20:10:00

BioMarin Pharmaceutical Inc. raised earnings guidance for the full year of 2021. For the year, the company now expects total revenues of $1,790 million to $1,880 million and GAAP Net Loss of $110 million to $60 million against total revenues of $1,750 million to $1,850 million and GAAP Net Loss of $130 million to $80 million expected previously.

BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress

2021-07-19 15:00:00

BioMarin Pharmaceutical Inc. announced new data for valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, in its positive pivotal study, GENEr8-1, during an oral presentation at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress. The pivotal study demonstrated superiority to Factor VIII prophylaxis in key clinical efficacy endpoints. With 134 participants, this is the large global Phase 3 study to date for gene therapy in hemophilia. All participants in the study received a single dose of valoctocogene roxaparvovec and completed a year or more of follow-up. Top-line one-year results from this study were previously communicated in January 2021. New data presented at ISTH include more details on annualized bleeding rate (ABR) in all study participants and annualized Factor VIII utilization rate, in terms of international units per kilogram per year (IU/kg/year) of replacement Factor VIII. Over 90% (N=134) of all participants in the GENEr8-1 study had an annualized bleed rate (ABR) of zero or a lower bleed rate than baseline after week 4 after treatment with valoctocogene roxaparvovec. New data presented at ISTH also include information on Factor VIII utilization after treatment with valoctocogene roxaparvovec. Mean annualized Factor VIII utilization rate, among a pre-specified group of prior participants in a non-interventional baseline observational study (rollover population; N=112) decreased from baseline on Factor VIII prophylaxis by 99% from 3961.2 (median 3754.4) to 56.9 (median 0) IU/kg/year after week 4 after treatment with valoctocogene roxaparvovec (p-value GENEr8-1 Study Description. The global Phase 3 GENEr8-1 study evaluates superiority of valoctocogene roxaparvovec at the 6e13 vg/kg dose compared to FVIII prophylactic therapy. All study participants had severe hemophilia A at baseline, defined as less than or equal to 1 IU/dL of Factor VIII activity. The study included 134 total participants, all of whom had a minimum of 12 months of follow-up at the time of the data cut. The first 22 participants were directly enrolled into the Phase 3 study, 17 of whom were HIV-negative and dosed at least 2 years prior to the data cut date (referred to as the subset). The remaining 112 participants (rollover population) completed at least six months in a separate non-interventional study to prospectively assess bleeding episodes, Factor VIII use, and health-related quality of life while receiving Factor VIII prophylaxis prior to rolling over to receive a single infusion of valoctocogene roxaparvovec in the GENEr8-1 study.

BioMarin Pharmaceutical Inc., Q2 2021 Earnings Call, Jul 28, 2021

2021-07-14 12:30:00

BioMarin Pharmaceutical Inc., Q2 2021 Earnings Call, Jul 28, 2021

JPMorgan Chase & Co., J.P. Morgan 12th Annual U.S. All Stars Conference, Sep 21, 2021 through Sep 23, 2021

2021-07-13 12:19:00

JPMorgan Chase & Co., J.P. Morgan 12th Annual U.S. All Stars Conference, Sep 21, 2021 through Sep 23, 2021.

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New York, United States.